THERAPY DOSSIER · th-aa65862c4b3d

Mimosa pudica leaf ethanolic extract (MPE)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27164910 ↗2016Reported benefit

Protective effect of Mimosa pudica L. in an L-arginine model of acute necrotising pancreatitis in rats.

RatChemical/toxinSprague-DawleyMaleOral400 mg/kg

Model: L-arginine-induced acute necrotising pancreatitis (two intraperitoneal injections of 2 g/kg L-arginine 1 h apart)

MPE reduced severity of acute necrotising pancreatitis, improving diagnostic markers, inflammation and oxidative stress, and promoted pancreatic repair with reduced fibrosis.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…